The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...
AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...
AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Aliada Therapeutics. With the completion of the ...
“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...
Hello from San Diego, where I always happen to be, but where this weekend I had the delight of hanging out with coworkers ...
The stock's fall snapped a two-day winning streak.
Tavapadon improved motor and daily living complications at week 26. The news comes nearly one month to the day after AbbVie ...
BofA reinstated coverage of AbbVie (ABBV) with a Neutral rating and $191 price target AbbVie is a relatively “quiet” stock with durable ...
A new survey from AbbVie digs into the emotional experience of a chronic lymphocytic leukemia (CLL) diagnosis and, according ...
AbbVie ABBV over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table ...
In a report released today, Steve Scala from TD Cowen maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback